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We conducted a systematic review of studies that used 
reverse transcription–PCR to diagnose norovirus (NoV) in-
fections in patients with mild or moderate (outpatient) and 
severe (hospitalized) diarrhea. NoVs accounted for 12% 
(95% conﬁ  dence interval [CI] 10%–15%) of severe gastro-
enteritis cases among children <5 years of age and 12% 
(95% CI 9%–15%) of mild and moderate diarrhea cases 
among persons of all ages. Of 19 studies among children <5 
years of age, 7 were in developing countries where pooled 
prevalence of severe NoV disease (12%) was comparable 
to that for industrialized countries (12%). We estimate that 
each year NoVs cause 64,000 episodes of diarrhea requir-
ing hospitalization and 900,000 clinic visits among children 
in industrialized countries, and up to 200,000 deaths of chil-
dren <5 years of age in developing countries. Future efforts 
should focus on developing targeted strategies, possibly 
even vaccines, for preventing NoV disease and better doc-
umenting their impact among children living in developing 
countries, where >95% of the deaths from diarrhea occur.
D
espite improved safety of food, water, and sanitation 
and aggressive promotion of noninvasive interventions 
(e.g., oral rehydration therapy) and prevention strategies 
(e.g., increased breastfeeding), diarrhea remains a common 
cause of illness worldwide. It accounts for ≈1.8 million an-
nual deaths in children <5 years of age (1). Reduction of this 
disease will require targeted prevention and treatment strate-
gies against the common agents causing severe diarrhea.
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Noroviruses (NoVs) and sapoviruses are genetically 
and antigenically diverse single-stranded RNA viruses that 
belong to 2 different genera (Norovirus and Sapovirus) in 
the family Caliciviridae and are collectively referred to as 
human caliciviruses (2). The prototype virus of the NoVs, 
Norwalk virus, was identiﬁ  ed in 1972. However, the in-
ability to cultivate these viruses in routine cell culture and 
the consequent challenges in developing sensitive nonmo-
lecular diagnostic assays hindered initial efforts to deﬁ  ne 
the epidemiology and assess the impact of disease associ-
ated with NoV infection. In the past 15 years, the avail-
ability of sensitive molecular diagnostic methods based on 
reverse transcription–PCR (RT-PCR) has allowed broader 
examination of the etiologic role of NoVs in epidemic and 
sporadic gastroenteritis (3,4).
Since the application of molecular assays, NoVs have 
been well-documented as the leading cause of epidemic 
gastroenteritis in all age groups, causing >90% of non-
bacterial and ≈50% of all-cause epidemic gastroenteritis 
worldwide (5). Recent studies that used improved diagnos-
tics have demonstrated that NoVs may also ﬁ  ll in the “diag-
nostic gap” in severe sporadic gastroenteritis among all age 
groups worldwide (6). Much of the misconception of NoV 
as an infrequent cause of severe sporadic diarrhea might 
also stem from studies undertaken before the mid-1990s 
that found low rates of NoV infection because available 
diagnostics such as electron microscopy and antigen detec-
tion assays had poor sensitivity. Recent data are emerging 
that are debunking these misconceptions, suggesting that 
the impact of NoV disease may be much greater than pre-
viously suspected and the disease may be more severe in 
some populations (4,6–8). However, because these novel 
assays are not typically available outside of reference labo-
ratories, the true global prevalence and potential economic 
impact of NoV disease remain unrecognized (3). To further 
understand the etiologic role of NoVs in sporadic diarrhea, 
we conducted a systematic review to identify studies that 
used similar inclusion criteria and molecular assays based 
on RT-PCR to detect NoVs in fecal specimens from pa-
tients with diarrhea.
Methods
We searched MEDLINE, EMBASE, and Google 
Scholar to identify studies published in English between 
January 1990 and February 2008. We used the following 
keywords: Norwalk, norovirus, Norwalk-like virus, human 
calicivirus, calicivirus, NLV, small round virus, and small 
round structured virus. We reviewed all abstracts to iden-
tify articles that assessed the prevalence of NoV among 
sporadic cases of diarrhea. To ensure complete capture of 
all relevant studies, we cross-referenced all articles from 
the bibliography of the selected articles. After reviewing 
each article, we selected studies that met the following 
inclusion criteria: 1) study duration was >1 year, and 2) 
study used RT-PCR to diagnose caliciviruses (NoV and 
sapovirus) or NoV in patients with diarrhea. We included 
studies that tested for caliciviruses, even when they did not 
differentiate between NoV and sapovirus. For these stud-
ies, we multiplied the proportion of caliciviruses detected 
in each study by the mean proportion of caliciviruses 
that were NoV among studies that differentiated between 
NoVs and sapoviruses to yield the estimated NoV preva-
lence in each study. We excluded studies that did not pro-
vide a denominator (i.e., the total number of patients with 
diarrhea in the study population) or that only conducted 
molecular analysis using a fraction of the fecal samples 
(online Technical Appendix 1, available from www.cdc.
gov/EID/content/14/8/1224-Techapp1.pdf). If the authors 
presented the data again in another study, only 1 study 
was included. See online Technical Appendix 2, available 
from www.cdc.gov/EID/content/14/8/1224-Techapp2.
pdf, for a list of all references used in the review but not 
cited in this article.
We stratiﬁ  ed studies into 2 settings: community or 
clinic-based (mild or moderate diarrhea) and hospital-based 
including emergency department and inpatients (severe 
diarrhea). We counted cases in which NoV was detected 
in the presence of >1 other pathogens (i.e., mixed infec-
tion) as NoV infection; however, we also present data on 
mixed infections, when available. Pooled proportions and 
95% conﬁ  dence intervals (CIs) of NoV-positive cases were 
calculated by using the random effects models (DerSimo-
nnian and Laird method, StatsDirect Ltd, Cheshire, UK). 
For the studies that included fecal testing on concurrent 
diarrhea-free controls, the pooled proportions were based 
on absolute difference in NoV detection rate between cases 
and controls, thus only including the fraction of cases at-
tributable to NoVs. The Cochran Q statistic and degrees of 
freedom (df) are presented as a measure of heterogeneity 
among studies. Analyses were conducted with StatsDirect 
version 2.5.7 (StatsDirect Ltd).
To calculate the number of outpatient NoV episodes 
and hospitalizations for children living in industrialized 
countries (where 23 of 31 studies in our review were con-
ducted), we multiplied the total number of estimated diar-
rhea episodes in each clinical setting by the pooled propor-
tion attributable to NoV based on the studies we reviewed 
to yield the number of NoV cases in each setting (9). No 
data exist on estimates of total diarrhea episodes in indus-
trialized countries. Thus, we divided the estimates of out-
patient and inpatient rotavirus episodes for industrialized 
countries, provided by Parashar et al. (9), by the propor-
tion of diarrhea episodes attributable to rotavirus (23% and 
42%, respectively) in the United States (10) and Europe 
(11) to yield the annual number of total diarrhea episodes 
in industrialized countries. To estimate the proportion of 
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outpatient (23%) and inpatient (42%) diarrhea episodes 
attributable to rotavirus, we assumed the midpoint of the 
proportion of gastroenteritis visits attributable to rotavirus 
in the United States (19% and 35%, respectively) and 7 
European countries (27% and 50% respectively) for each 
setting, respectively.
To estimate NoV-associated deaths and hospitaliza-
tions among children in developing countries, we multiplied 
global estimates of diarrhea deaths (1) and hospitalizations 
(9) by the pooled proportion of NoV among children <5 
years of age hospitalized with diarrhea. Data from devel-
oping countries were sparse on fraction of NoV-associated 
diarrhea episodes in the outpatient setting.
Results
Overall, we reviewed 235 studies and identiﬁ  ed 31 
original studies that met our inclusion criteria (Tables 1, 2) 
(6,12–41). Of these 31 studies, 20 were conducted in high-
income countries, 2 were high-middle-income countries, 5 
were low-middle income, and 4 were low-income countries, 
based on World Bank classiﬁ  cation of economies (42). The 
duration of these studies was 1–5 years. Fourteen studies 
tested only for NoV (13,14,19,21,22,27,29,30,35,37–41); 
17 tested for NoV and sapovirus (6,12,15–18,20,23–26, 
28,31–34,36). Among 13 of 17 studies that tested for and 
presented separate detection rates on both caliciviruses, 
NoV was detected in 84.5% and 88.5% of the community- 
and hospital-based studies, respectively (6,15,16,20,23–26, 
31–34,36). In these 13 studies, 69%–90% of the outpatient 
cases and 61%–100% of the hospital cases with calicivi-
ruses were identiﬁ  ed as NoV.
Illness by Age and Setting
Community- or Clinic-based Cases 
(i.e., Mild and Moderate Diarrhea)
Among the 13 studies of community- or clinic-based 
diarrhea cases, NoVs were detected in 5%–36% of cases; 
pooled proportion was 12% (95% CI 9%–15%; Cochran 
Q 335; df 12) (Figure 1). Five studies enrolled both adults 
and children, and 8 studies focused only on children, each 
with varying age ranges (overall range 0–13 years). In the 8 
studies that assessed mixed infections, 0.4%–6.5% (median 
1.1%) of the gastroenteritis cases were also positive for an-
other viral or bacterial pathogen (Table 1).
Hospitalizations (i.e., Severe Diarrhea)
Twenty-three studies [hospital-based (n = 21); emer-
gency department–based (n = 1); both (n = 1)] evaluated 
NoV disease among hospitalized diarrhea case-patients in 
whom the proportion of NoV disease ranged from 3% to 
31%; pooled proportion was 11% (95% CI 8%–14%). Most 
(n = 19) of these studies of severe diarrhea cases focused 
on children <5 years of age, and the pooled proportion of 
NoV disease in these studies was 12% (95% CI 10%–15%) 
(Figure 2). In the 5 studies that assessed for multiple enter-
ic pathogens, mixed infections were detected in 0%–24% 
(median 3.7%) of the gastroenteritis cases (Table 2).
Most (>95%) of the world’s diarrheal deaths occur in 
low-middle– and low-income countries (43). In our review, 
7 of 19 studies assessing prevalence of severe NoV dis-
ease among children <5 years of age were conducted in 
these countries (23,25,28,33,34,36,39). Pooled proportions 
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Table 1. Summary of studies examining prevalence of NoV in persons with severe sporadic AGE, using RT-PCR for studies >12 


























(6)† England 12† All 2,422 871 36.0 –‡ – 2,205 16.2
(12)§ France 26 <13 414 49 11.8 27 6.5 50 0.0
(15) Netherlands 12 All 709 114 16.1 – – 669 5.2
(16) Netherlands 36 All 857 43 5.0 – – 574 1.0
(13)¶ Hong Kong 12 All 995 92 9.2 – – – –
(14) Australia 17 All 638 73 11.4 7 1.1 – –
(33)¶ India 36 <5 500 38 7.6 5 1.0 173 4.0
(18)§¶ Chile 31 <5 274 15 5.5 – – – –
(17)§ Finland 21 <2 1,477 264 17.8 13 0.9 47 0.0
(20) Japan 12 <11 557 106 19.0 12 2.2 – –
(21) Japan 12 <11 402 58 14.4 – – – –
(19) Japan 12 <5 752 139 18.5 3 0.4 – –
(34)¶# Tunisia 15 <12 380 49 12.9 13 3.4 – –
*NoV, norovirus; AGE, acute gastroenteritis; RT-PCR, reverse transcription–PCR; Ref, reference; –. not assessed in the study. Studies were of >12 
months’ duration. 
†Using RT-PCR, tested stored specimens from a previous study that used electron microscopy for NoV detection; enrollment was staggered over 29 
months with 70 clinics, each enrolling patients for 12 months. 
‡Tested for mixed pathogens but did not provide pathogen-specific results. 
§NoV prevalance in these studies was estimated by multiplying the calicivirus prevalance by average proportion of caliciviruses determined to be NoV 
(84.5%) among outpatient studies reporting NoV and sapovirus results separately. 
¶O’Ryan et al. (18) included clinic-, emergency department–, and hospital-based patients; Lau et al. (13), Monica et al. (33), and Sdiri-Loulizi et al. (34)
included community/clinic- and hospital-based patients. Only community and clinic data are presented here. 
#Age- and setting-specific data were obtained through personal communication with the author. Human Noroviruses in Sporadic Gastroenteritis
for NoV-associated childhood hospitalization were 12% 
(95% CI 8%–17%) among low-middle and low income in 
comparison to 12% (95% CI 9%–16%) for high- and high-
middle–income countries.
Studies with Concurrent Controls
Concurrent diarrhea-free controls were enrolled in 9 of 
31 studies, and NoVs were detected in 0%–16% (median 
4%) of the controls (6,12,15–18,27,28,33). On the basis of 
the difference in detection rate between cases and controls 
in these studies, we estimate that the fraction of cases at-
tributable to NoV in these studies was 4%–20% (median 
12%) for mild to moderate diarrhea and 2%–26% (median 
11%) for severe diarrhea.
Strain Characterization
Overall, 19 studies characterized the NoV strains 
by using nucleotide sequencing (13,14,17,19–21, 
23,24,26,27,32–36,38–41). Among NoV cases, strains be-
longing to NoV genogroup (G) II were the most common 
(range 75%–100%). With the exception of 2 studies, the 
overwhelming majority of the NoV strains belonged to the 
GII.4 cluster (21,23). In Malawi (1 of the 4 low-income 
countries in our analysis), GII.3 strains were detected in 
69% of the samples that were sequenced (23). Similarly, 
in 2006, novel GII.3 strains were identiﬁ  ed in 44% of the 
samples in a clinic-based study in Japan (21). Through ge-
netic characterization, the authors demonstrated that these 
GII.3 strains likely were recombinant strains that appeared 
over a period of 4 months.
Estimated Prevalence of NoV Disease in Children
We estimate that each year NoVs cause ≈900,000 
episodes of gastroenteritis that require a clinic visit and 
≈64,000 hospitalizations among children <5 years of age 
residing in high-income countries (Table 3). If one as-
sumes that the proportion of annual childhood diarrhea-
associated hospitalizations (≈124 million) and deaths 
(≈1.8 million) in developing countries approximates the 
overall proportion of children (12.1%) with severe NoV 
illness in our review, NoVs may cause up to 1.1 million 
hospitalizations and 218,000 deaths each year in children 
in developing countries.
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Table 2. Summary of studies that examined prevalence of NoV in persons with severe sporadic AGE, emergency department visits 



























 ( 22) Spain 12 <14 363 16 4.4 1 0.3 – –
 ( 18)†‡ Chile 25 and 17§ <5 248 23 9.3 – – 80 1.3
Hospital
 ( 35) Italy 12 <3 365 93 25.5 35 9.6 – –
 ( 23) Malawi 12 <5 398 26 6.5 12 3.0 – –
 ( 24) Vietnam 12 <15 1,339 72 5.4 0 0.0 – –
 ( 25) Thailand 12 <5 105 8 7.6 – – – –
 ( 36) Thailand 20 <5 248 35 14.1 – – – –
 ( 26) Australia 60 <5 1,233 108 8.8 – – – –
 ( 13)‡ Hong Kong 12 All 735 123 16.7 – – – –
 ( 37) South Korea 24 <5 962 132 13.7 18 1.9 – –
 ( 33)‡ India 36 <5 350 53 15.1 26 7.4 173 4.0
 ( 27) Germany 12 <16¶ 217 45 20.7 – – 50 4.0
 ( 38) Japan 24 Children 500 66 13.2 2 0.4 – –
 ( 18)‡ Chile 25 and 17§ <5 162 8 4.9 – – 50 0.0
 ( 39) Madagascar 13 <5 237 14 5.9 0 0.0 – –
 ( 27)† Peru 24 <5 233 72 30.7 56 23.9 248 11.4
 ( 29) Spain 12 <5 656 79 12.0 36 5.5 – –
 ( 30) Australia 36 <5 360 9 2.5 – – – –
 ( 34)‡# Tunisia 27 <12 252 61 24.2 12 4.8 – –
 ( 40) Brazil 12 <5 318 65 20.4 14 4.4 – –
 ( 31) South Africa 48 All 1,296 32 2.5 – – – –
 ( 41) South Korea 12 <5 762 114 15.0 – – – –
 ( 31) USA 24 <4 1,840 131 7.1 – – –
*NoV, norovirus; AGE, acute gastroenteritis; RT-PCR, reverse transcription–PCR; Ref, reference; –, not assessed in the study.  
†NoV prevalence (total and mixed alone) in these studies was estimated by multiplying the calicivirus prevalence by average proportion fo caliciviruses 
determined to be NoV (88.5%) among hospital-based studies reporting NoV and sapovirus results separately.  
‡O’Ryan et al. (18) included clinic-, emergency department–, and hospital-based patients; Lau et al. (13), Monica et al. (33), and Sdiri-Loulizi et al. (34)
included community/clinic- and hospital-based patients. Only emergency department and hospitalization data are presented here. 
§Included 2 hospitals with 25- and 17-month enrollment periods. 
¶98% (213 of 217) of the case-patients were <5 y of age. 
#Age- and setting-specific data were obtained through personal communication with the author. RESEARCH
Discussion
This systematic review of studies that used RT-PCR for 
detection of NoVs in fecal specimens clearly indicates that 
these viruses play an important role in the cause of both mild 
and severe gastroenteritis worldwide. In 1979, Greenberg et 
al. demonstrated that virtually all children in various coun-
tries worldwide acquired antibodies to NoVs by 5–15 years 
of age (online Technical Appendix 2). However, despite 
strong evidence that NoV infection was ubiquitous, detection 
rates in children hospitalized with diarrhea were low in early 
studies that used electron microscopy and antigen assays (4). 
The advent of conventional RT-PCR for the diagnosis of 
NoVs has substantially changed our understanding of their 
epidemiology. Among all reported studies that used conven-
tional RT-PCR, NoVs were detected in ≈12% of children 
<5 years of age with severe diarrhea, which suggests that 
these viruses are the second most common cause of severe 
childhood gastroenteritis, following rotavirus. In addition, 
although some studies suggest that NoV infections in the 
community are slightly less severe than rotavirus infections, 
data also exist to suggest that these childhood infections may 
be similar in severity, which may particularly apply to hospi-
talized children (online Technical Appendix 2). On the basis 
of the pooled detection rates of NoV in our review, we would 
estimate that in the United States alone NoVs may account 
for >235,000 clinic visits, 91,000 emergency room visits, 
and 23,000 hospitalizations among children <5 years of age 
(10). Limited data from developing countries are available 
to make ﬁ  rm estimates, but NoV disease may cause >1 mil-
lion hospitalizations and 200,000 deaths each year among 
children <5 years of age.
Although these ﬁ  gures provide a preliminary indication 
of the substantial magnitude of illness from NoV disease, 
they may underestimate the true extent of disease. Evidence 
suggests that detection of NoVs in fecal specimens by con-
ventional RT-PCRs may be limited by factors such as low 
virus concentrations in feces, improper specimen storage, 
inefﬁ  cient viral RNA extraction, presence of fecal reverse 
transcriptase inhibitors, and use of different primers (online 
Technical Appendix 2). In addition, NoVs are extremely 
genetically diverse and none of the reported conventional 
RT-PCR assays is able to detect all strains (online Tech-
nical Appendix 2). These hypotheses are supported by the 
ﬁ  ndings of an evaluation of children with gastroenteritis in 
Peru in which both RT-PCR testing of fecal specimens and 
serologic assays were used to assess NoV infection, and se-
rologic testing was found to increase the rates of NoV de-
tection from 35% with fecal testing alone to 55% by use of 
either assay (28). A recent validation study comparing state-
of-the-art real-time RT-PCR with conventional RT-PCR 
found that the sensitivity of real-time RT-PCR was greater 
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Figure 1. Summary of studies assessing proportion of norovirus 
(NoV)-positive fecal samples among persons with community 
and outpatient cases of sporadic diarrhea (all ages). *Lau et al. 
(13), O’Ryan et al. (18), Monica et al. (33), and Sdiri-Loulizi et 
al. (34) included outpatient and emergency department/hospital 
patients, but only outpatient data are included in this ﬁ  gure. 
†Pooled proportion calculated by using the random effects model 
(DerSimonian and Laird method, StatsDirect Ltd, Cheshire, UK). For 
studies that included controls, prevalence of NoV among controls 
was subtracted from prevalence of NoV among case-patients. CI, 
conﬁ  dence interval.
Figure 2. Summary of studies assessing proportion of norovirus 
(NoV)-positive fecal samples among hospitalized and emergency 
department cases of children <5 years of age who had sporadic 
diarrhea. *Lau et al. (13), O’Ryan et al. (18), Monica et al. (33), 
and Sdiri-Loulizi et al. (34) included outpatient and emergency 
department/hospital patients, but only inpatient data are included 
in this ﬁ  gure. †Oh et al. (27), 98% (213 of 217) of the case-patients 
were <5 years of age. ‡Pooled proportion calculated using the 
random effects model (DerSimonian and Laird method (StatsDirect 
Ltd, Cheshire, UK). For studies that included controls, prevalence 
of NoV among controls was subtracted from prevalence of NoV 
among case-patients. CI, conﬁ  dence interval.
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than that of the conventional method, especially for samples 
containing low NoV concentrations or RT-PCR inhibitors 
(online Technical Appendix 2). The broader application of 
real-time RT-PCR assays to diagnose NoV among children 
hospitalized with gastroenteritis should provide better esti-
mates of the true prevalence of disease.
Some factors could have led us to overestimate the 
extent of sporadic NoV disease. Our estimates of sporadic 
NoV disease prevalence are based on a review of active 
surveillance data of all diarrhea cases and do not exclude 
cases originating from an outbreak. In a few studies, NoVs 
were detected in patients who were co-infected with anoth-
er pathogen, and only a limited number of studies enrolled 
concurrent healthy controls, thus making it difﬁ  cult to de-
termine the fraction of diarrhea cases truly attributable to 
NoV. Among all studies testing for co-infections, however, 
the median rate of detecting another pathogen in addition 
to NoV was low (2%). This ﬁ  nding, combined with the fact 
that most studies only assessed for NoV among samples 
that previously tested negative for other bacterial and vi-
ral pathogens, suggests that our overall pooled proportion 
attributable to NoVs is unlikely to be much lower. In ad-
dition, for the studies that enrolled diarrhea-free controls, 
we subtracted control prevalence from the case prevalence 
of NoV disease when calculating the overall pooled esti-
mate. Lastly, other unmeasured factors underestimating 
disease prevalence that could not be accounted for, such as 
inefﬁ  cient primers, low virus shedding, delays in specimen 
collection, and lack of a sensitive case-deﬁ  nition are also 
likely to exist in these studies.
The heterogeneity in the NoV literature is evident and 
should be considered when interpreting the results of this 
review. Our systematic approach and strict inclusion cri-
teria likely reduced heterogeneity but do not eliminate bi-
ases in the original studies, diversity in study design and 
population, and publication bias. Nonetheless, the ﬁ  ndings 
of this review suggest that NoVs are a frequent cause of 
mild and severe sporadic gastroenteritis among children 
in high- and middle-income countries. In addition, hospi-
tal studies in our review only assessed patients admitted 
with diarrhea. Because of the highly infectious nature of 
NoVs, substantial additional health and economic effects 
would also occur from nosocomial disease and outbreaks in 
healthcare facilities, as previously identiﬁ  ed by Lopman et 
al (7). NoVs are also a frequent cause of severe illness and 
death from diarrhea among children in developing coun-
tries, although ﬁ  rm conclusions cannot be made because 
of limited data. Systematic evaluations that use broadly re-
active, state-of-the-art diagnostic assays, with concurrent 
evaluation of healthy controls and examination of poten-
tial co-infection, are needed to fully understand the role of 
NoVs in the etiology of sporadic childhood gastroenteritis. 
These evaluations are especially necessary in developing 
countries, where diarrhea remains a leading cause of child-
hood death, causing >1.8 million annual deaths (1).
The increasing evidence documenting the magnitude 
of the NoV disease prevalence provides support for consid-
ering targeted interventions, such as vaccines, for reducing 
the extent of this illness among young children. However, if 
one considers that NoV frequently causes both sporadic and 
epidemic gastroenteritis and can affect all age groups, some 
other potential targets for vaccination may include elderly 
persons in nursing homes, who are vulnerable to severe 
complications, and military recruits, in whom sporadic and 
epidemic NoV disease is known to incur substantial illness 
and ﬁ  nancial costs from work disruption (7; online Tech-
nical Appendix 2). The development of vaccines against 
NoVs will likely be challenging because the immunity to 
these viruses and the diversity and evolution of circulat-
ing strains are incompletely understood (online Technical 
Appendix 2). However, genotype II, cluster 4 NoV strains 
appeared to be by far the most prevalent strains among the 
studies we reviewed, and these strains may be the primary 
targets for vaccine development. 
Carefully designed epidemiologic studies that evalu-
ate NoV prevalence in children with diarrhea and a suitable 
comparison group and that use sensitive molecular assays 
will help further deﬁ  ne target groups that would beneﬁ  t from 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 8, August 2008  1229 
Table 3. Estimates of annual number of episodes of norovirus-associated diarrhea among children <5 years of age in industrialized




Pooled proportion of 
episodes attributable to 
noroviruses, % 
Total no. norovirus 
episodes
Annual incidence per 
100,000 children†‡ 
Industrialized countries† 
Outpatient 7,743,000 11.7 906,000 1,665
Inpatient 531,000 12.1 64,200 118
Developing countries‡§ 
Inpatient 9,015,000 12.1 1,091,000 197
Deaths 1,800,000 12.1 218,000 39
*Refer to Methods section of article.  
†Industrialized countries’ incidence based on UNICEF 2003 population estimates of  54,425,000 children <5 y of age in developing countries 
(www.unicef.org/sowc05/english/Developingregional.html). 
‡Developing countries’ incidence based on UNICEF 2003 population estimates of 552,742,000 children <5 y of age in industrialized
(www.unicef.org/sowc05/english/Industrializedregional.html).  
§Data from developing countries were sparse on fraction of norovirus-associated diarrhea episodes in the outpatient setting. RESEARCH
vaccines and other interventions. A particularly pressing 
need exists for better quantifying the extent of severe no-
rovirus disease among children in developing countries and 
identifying prevention strategies to help reduce the preva-
lence of deaths from diarrhea in the poorest countries.
Dr Patel is a medical epidemiologist with the Epidemiology 
Branch, Division of Viral Diseases, National Center for Immu-
nizations and Respiratory Diseases, Centers for Disease Control 
and Prevention. His research focuses on the epidemiology of viral 
gastroenteritis and methods for its prevention and control.
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